Endpoint Clinical announced an enhancement to its proprietary Pulse platform, remodeling how its interactive response technology (IRT) is applied to clinical trials.
“Since the initiation of Endpoint in 2009, we have been continuously improving IRT through our organic growth model,” Chuck Harris, CEO said. “The result is the industry’s most integrated and powerful combination of patient and clinical supply management.”
Endpoint recently combined the features of its configurable IRT platform, Pulse, with its global inventory management tool, Drive, into a single solution. It extends IRT accessibility and affordability to clients’ entire clinical development portfolio, including investigator initiated trials (IIT) and early-phase, late-phase and compassionate use studies.
The Pulse-Drive fusion shifts that paradigm to look across protocols, which provides access to novel functionality supporting operations and regulatory needs such as supply pooling, temperature-excursion management, and therapeutic- and compound-level reporting.
“One of the key factors to the successful evolution of endpoint’s products is our leadership’s laser-like focus on the IRT space and how it should be transformed,” Christine Oliver, COO said. “We have built our platforms in-house through an unmatched understanding of system integration, hands-on experience in supply chain management, and a relentless focus on the ever-evolving challenges in clinical trial design.”